FY27 Revenue Growth: 10-15%
Management maintained full-year guidance targeting 10-15% revenue growth, supported by expected volume recovery in Europe and continued momentum in NAFTA/LATAM markets.
SHARDACROP / guidance tracker
Keep management guidance in view.
Sharda Cropchem · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
revenue
FY27 Volume Growth: 5-10%
On volume front, management expects 5-10% volume growth for the year, implying the remainder of FY27 should see better volume recovery after Q1 weakness.
FY27 EBITDA Margin: 18-20%
Company targets EBITDA margin in the 18-20% range for FY27, consistent with recent performance trajectory despite Q1 being at 16.6% due to unfavorable product mix.
FY27 Gross Margin: ~35%
Management guides gross margin around 35% for the year, noting that Q1's 36.7% may moderate as Europe recovers and product mix normalizes.
FY27 Revenue Growth: 15-20%
Management expects revenue growth of 15-20% in FY27, with volume growth of approximately 15% achievable. Growth to be driven by continued demand recovery, pricing improvement, and new registrations.
EBITDA Margin: 18-20% range for FY26
Company is on track to maintain healthy EBITDA margins in the range of 18-20% for FY26, with potential for further improvement in FY27 as gross margins may go up still further.
Gross Margin: ~35% sustainable
Gross margins expected to remain in similar range (~35%) for FY26, with management indicating it could potentially improve further in FY27.
FY27 Capex: Rs 450-500 crore
Capital expenditure for FY27 is guided in the range of Rs 450-500 crore, though management noted uncertainty due to registration process variables.